<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">Secondary malignancies</z:e> after marrow transplantation have been observed in 20 patients: 19 patients underwent marrow transplantation for the treatment of a hemopoietic <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> and one for <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> but three were given total body irradiation at doses of 8.0-15.75 Gy as part of the conditioning regimen </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">Secondary malignancies</z:e> were composed of three groups: (a) Six patients had recurrence of <z:hpo ids='HP_0001909'>leukemia</z:hpo> (three <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic, two <z:hpo ids='HP_0011009'>acute</z:hpo> myeloblastic, and one <z:hpo ids='HP_0011010'>chronic</z:hpo> myelocytic) in cells of donor origin 62-1074 days after grafting </plain></SENT>
<SENT sid="3" pm="."><plain>(b) Eight patients developed <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> (four of <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> <z:hpo ids='HP_0100242'>sarcoma</z:hpo> type, one lymphoblastic, one follicular center cell, and one Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and one <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo>) 54-730 days after grafting </plain></SENT>
<SENT sid="4" pm="."><plain>In four of seven patients with appropriate studies these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were of donor-cell origin and in three of four tested the cells contained Epstein-Barr virus genome or expressed <z:mp ids='MP_0001799'>viral</z:mp> antigens </plain></SENT>
<SENT sid="5" pm="."><plain>(c) Six patients developed <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> (two <z:hpo ids='HP_0100843'>glioblastoma</z:hpo> multiforme, two <z:mp ids='MP_0009308'>adenocarcinomas</z:mp>, one <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo>, and one <z:hpo ids='HP_0100242'>sarcoma</z:hpo>) 347-1875 days after grafting </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> but two patients (one with <z:hpo ids='HP_0100843'>glioblastoma</z:hpo> and one with <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo>) have died </plain></SENT>
<SENT sid="7" pm="."><plain>These data suggest that patients undergoing marrow transplantation for a hemopoietic <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> may be at risk of developing <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">secondary malignancies</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The etiology appears to be multifactorial, including irradiation, immunosuppression, <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">Epstein-Barr virus infections</z:e>, and other factors </plain></SENT>
</text></document>